The EPS beat and $1B buyback provide near-term support, but the 35% revenue decline and widening losses underscore the COVID-19 revenue cliff. Watch for pumitamig Phase 2 data at ASCO (May 29-June 2) and gotistobart interim Phase 3 data in 2026, positive readouts could re-rate the stock on oncology optionality. The manufacturing restructuring signals management is serious about cost discipline, but execution risk is high.
BNTX drugs
BNTX drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · May 5 $95.50entry
- T+1 · 7mo ago −0.25%α −1.64% · $95.26
- T+5 · 6mo ago −2.26%α −4.25% · $93.34
- T+20 · 6mo ago −6.66%α −11.61% · $89.14
- T+60 · 4mo ago −2.77%α −5.51% · $92.85
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
BioNTech reported Q1 2026 revenue of €118.1M (down 35% YoY) and a GAAP net loss of €531.9M (diluted EPS -€2.10), which beat the consensus EPS estimate of -$1.92 by ~35%. The company reaffirmed full-year 2026 revenue guidance of €2.0B-€2.3B and announced a planned $1B share repurchase program and a major manufacturing footprint consolidation expected to yield ~€500M in annual savings by 2029. However, the core COVID-19 vaccine business continues to decline, and the oncology pipeline, while advancing with multiple pivotal trial initiations, remains pre-commercial.
Key Financial Metrics
Key Facts
- Q1 2026 revenue €118.1M vs €182.8M YoY (-35%), driven by lower COVID-19 vaccine sales
- GAAP diluted EPS -€2.10 (-$2.46) vs consensus -$1.92, a 34.9% beat
- Net loss widened to -€531.9M from -€415.8M YoY; adjusted net loss -€494.6M
- Reaffirmed FY2026 revenue guidance €2.0B-€2.3B and adjusted R&D spend €2.2B-€2.5B
- Planned $1.0B ADS repurchase program over 12 months for capital efficiency
- Manufacturing footprint consolidation to exit Idar-Oberstein, Marburg, Singapore, and CureVac sites, affecting ~1,860 positions; ~€500M annual savings targeted by 2029
- Five pivotal trials for pumitamig (PD-L1/VEGF-A bispecific) initiated in Q1 2026 in collaboration with BMS
- Cash, cash equivalents, and security investments of €16.8B as of March 31, 2026
- Co-founders Sahin and Türeci to transition to new mRNA company by end of 2026; CEO search initiated
Financial Impact
Revenue decline of €64.7M YoY (-35%); net loss increased by €116.1M; $1B buyback authorized; ~€500M annual cost savings targeted by 2029
Risk Factors
- COVID-19 vaccine revenue continues to decline faster than oncology pipeline can offset
- Manufacturing consolidation may incur significant upfront exit costs and operational disruption
- Co-founder transition creates leadership uncertainty; new CEO appointment is a key overhang
- Oncology pipeline remains pre-revenue; late-stage trial failures would reset valuation
- $1B buyback may be viewed as capital allocation signal but does not fix declining fundamentals
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3287464 |
Track record
38 reports on BNTX
5 of 8 bullish or bearish reports moved the stock their way by T+60. Best: +25.10% at T+20 after the Mar 24, 2026 report. 11 of 16 went positive at some point.
Filters
- Nov 10, 20266d ago 6-K Neutral 4/10 Entry $87.21 Now $85.26 −2.24% settles Feb 8
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago 6-K Neutral 5/10 No price data
- Nov 3, 202613d ago Press Release Neutral 5/10 Entry $86.92 Now $85.26 −1.91% settles Feb 1
- Oct 29, 202618d ago Institutional Cluster Mixed 3/10 Entry $89.13 Now $85.26 −4.34% settles Jan 27
- Oct 26, 202621d ago 6-K Bullish 5/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 26, 202621d ago 6-K Bearish 5/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 26, 202621d ago Press Release Bearish 6/10 Entry $86.86 Now $85.26 +1.84% settles Jan 22
- Oct 25, 202622d ago Press Release Bullish 6/10 Entry $86.86 Now $85.26 −1.84% settles Jan 22
- Oct 22, 202625d ago 6-K Neutral 5/10 Entry $89.67 Now $85.26 −4.92% settles Jan 20
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers